样式: 排序: IF: - GO 导出 标记为已读
-
Dupilumab for chronic actinic dermatitis: A case series and review of the literature Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-17 Zachary Holmes, Peter Foley, Chris Baker, Benjamin S. Daniel
-
Use of biologics for psoriasis in solid organ transplant recipients Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-16 Marta Costa Blasco, Claire Doyle, Sophie Diong, Siona Ni Raghallaigh
Biologics have significantly advanced the treatment of inflammatory disorders, including psoriasis. However, their use in immunosuppressed patients, such as those with solid‐organ transplants, is less understood. These patients often face dermatological issues, but inflammatory skin diseases are rare due to their immunosuppressive treatments. Our study aims to assess biologics' effectiveness in such
-
Successful use of adalimumab in treating granuloma faciale resistant to traditional therapies Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-15 Martina Mussi, Corrado Zengarini, Filippo Viviani, Lidia Sacchelli, Alessandro Pileri, Federico Bardazzi
-
Dermatitis and prolonged dysesthesia from the poisonous wood nettle, Dendrocnide meyeniana (Urticaceae) Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-15 Johannes F. Dayrit, Bryan Edgar K. Guevara, Lunardi Bintanjoyo, Scott A. Norton
-
Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-15 Nisha V. Parmar, Anwar Al Hammadi
Dyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects. Tralokinumab is FDA‐approved for the treatment of atopic dermatitis
-
Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-10 Giorgia Salvia, Matteo Bevilacqua, Flavia Manzo Margiotta, Alessandra Michelucci, Giammarco Granieri, Cristian Fidanzi, Valentina Dini, Marco Romanelli, Carlo Mazzatenta
-
Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-10 Guiovana Fernanda Osorio‐Gómez, Juan Ortiz‐Álvarez, Delia Diaz‐Ceca, Cesar Guijarro‐Sánchez, Julián Conejo‐Mir Sánchez, Pablo Fernández Crehuet
IntroductionThe use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF‐alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL‐17, thus having a promising role in the treatment of HS.Material and methodsA multicenter retrospective observational open‐label
-
Nasal ala V‐Y island flap with a superior vascular pedicle based on inferior perforators of the superior alar artery Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-08 Jazlyn Read, Dougal Coates, John Pagliaro, Zoran Gaspar
For small defects of the anterior nasal ala, a V‐Y pedicle advancement flap within the subunit is a useful repair option. Here we propose a modification of this technique, utilising careful dissection to identify inferior perforators of the superior alar artery. Basing this flap on a visualised vascular pedicle aims to prevent common complications of internal mucosal buckling and free margin notching
-
Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-08 Francisco José Navarro‐Triviño, María Salazar‐Nievas, Juan Luis Sanz‐Cabanillas, Cintia Arjona‐Aguilera
Background/ObjectivesThe evaluation of the efficacy and safety of new molecules for atopic dermatitis (AD) in real clinical practice is very important to obtain information that clinical trials (EECC) lack. The pattern of AD in the head and neck (H&N) continues to be a challenge in treatment today, despite the new molecules, and real‐life data on the use of tralokinumab is still missing. This is the
-
Can we manage the melanocytic lesions with peripheral globules according to the grade of dysplasia? Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-04 Ceylan Avcı, Gülfem Akın, Banu Lebe, Mustafa Turhan Şahin, Emel Fetil
Background/ObjectivesAlthough excision of melanocytic nevi with high‐grade dysplasia is recommended by the World Health Organization (WHO), clinical studies investigating the approach based on the grading dysplasia of melanocytic lesions with peripheral globules (PGs) are lacking. We investigated the grades of dysplasia and their distinguishable dermoscopic and clinical features to provide accurate
-
Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-04-04 Hannah Godfrey, Patrick Jedlowski, Rebecca Thiede
Background/ObjectivesThe immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the
-
Extensive and deep granulomatous ulcers as an atypical manifestation of cartilage‐hair hypoplasia syndrome: A diagnostic and therapeutic challenge Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-28 Eduardo Rozas‐Muñoz, Rodrigo Blamey‐Diaz, Ana Maria Gallardo‐Olivos, Javiera Jerez, Juan‐Andres Madariaga
Cartilage hypoplasia syndrome is a primary immunodeficiency disease characterized by short stature, hypoplastic hair and a variable degree of immunodeficiency. Noninfectious cutaneous granulomas represent an uncommon yet well‐recognized manifestation within the spectrum of primary immunodeficiency diseases. However, cutaneous granulomas as a manifestation of cartilage‐hair hypoplasia syndrome, are
-
A case of nodular lichen myxedematosus Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-26 Kapil Subedi, Kashini Andrew, Pui Chi Lee
-
Naevoid miliaria profunda, successfully treated with botulinum toxin Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-26 William Berry, Colleen D'Arcy, Belinda Welsh, David Orchard, Philip S. Bekhor, Susan J. Robertson
-
The representation of skin of colour in the Australasian Journal of Dermatology Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-26 Harriet Kennedy, Loimata Fa'alogo‐Lilo
BACKGROUND Skin of colour (SoC) is underrepresented in dermatological literature with an associated reduction in clinician confidence diagnosing and managing skin conditions in patients with SoC.1-3 It is reported that half of Irish dermatology clinicians are not confident in diagnosing patients with SoC.1 Furthermore, confidence varies with the clinical context and a 2018 study found 85% of Australian
-
Is vitiligo associated with an increased risk of cardiovascular outcomes? Perceptions from a population‐based study Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-26 Khalaf Kridin, Niv Kafri, Arnon D. Cohen
While some studies have shown an association of vitiligo with obesity, dyslipidaemia and metabolic syndrome,1, 2 the risk of cardiovascular diseases among patients with vitiligo remains a scope of controversy. This study aimed to investigate the risk of myocardial infarction (MI), cerebrovascular accident (CVA), peripheral vascular disease (PVD) and pulmonary embolism (PE) in patients with vitiligo
-
Drug survival of biologics in psoriasis: An Australian multicentre retrospective study Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-21 Samantha Ting, Patricia Lowe, Annika Smith, Pablo Fernández‐Peñas
BackgroundDrug survival, which refers to the time from treatment initiation to discontinuation, provides a surrogate measure of the effectiveness of a biologic in a real‐world setting (J Invest Dermatol, 2015, 135, 1). The aim of this study was to determine the drug survival of biologics that are currently available in Australia. We also analysed the treatment efficacy of these biologics and reasons
-
Atopic dermatitis treated safely with dupilumab during pregnancy and lactation: A case series of four patients Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-21 Narang Hong, So Yun Park, Hyung Don Kook, Dong Heon Lee, Hye Jung Jung, Mi Youn Park, Jiyoung Ahn
CONFLICT OF INTEREST STATEMENT None.
-
Bullous Amyloidosis as a cutaneous feature of Familial Lysozyme Amyloidosis Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-20 R. Islam, L. Abbott, A. Potter, C. Thomas
We present the case of a 56-year-old female Day 1 post-donation after circulatory death (DCD) renal transplant with skin fragility and tense bullae, both secondary to lysozyme amyloidosis (ALys). She was systemically well and had no pruritus or pain. Her past medical history was significant for orthotopic liver transplant and splenectomy 20 years ago. Liver immunohistochemical staining using a panel
-
Spitz nevus puzzle: Red ink tattoo unveiling rare plexiform variants Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-20 Luca Bettolini, Stefano Bighetti, Sara Rovaris, Iacopo Ghini, Piergiacomo Calzavara‐Pinton, Vincenzo Maione
-
General practitioner prescription patterns for atopic eczema in children—Are they affected by telemedicine advice? Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-14 Geoffrey Ying, Karen Koch
Traditionally, patients presenting to primary care with severe eczema would be referred to a dermatology clinic for an in‐person specialist appointment. With the rise of teledermatology, dermatologists are instead dispensing tailored written advice based on information provided in the referral. However, there is currently minimal literature assessing whether this advice translates into relevant prescriptions
-
Vulval dermatoses: A review of referrals to dermatology Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-14 Sophie Warner, Amanda Oakley
We undertook a retrospective observational review of patients referred to a tertiary dermatology department with vulval complaints over 12 months. The most common provisional diagnoses made by the referrer and final dermatology diagnoses were lichen sclerosus (54% and 38%), dermatitis (12.7% and 16.5%) and psoriasis (5.1% and 6.3%). Referrers may benefit from further education about skin diseases of
-
Diagnostic delay in hidradenitis suppurativa: A systematic review and novel data from a Greek cohort Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-14 Aikaterini Tsentemeidou, Efstratios Vakirlis, Katerina Bakirtzi, Themis Chatzi‐Sotiriou, Aimilios Lallas, Dimitra Kiritsi, Elena Sotiriou
The age at first presentation of hidradenitis suppurativa (HS), a chronic debilitating autoinflammatory skin disease, significantly differs from the age at diagnosis, often by several years.1, 2 On one hand, patients may delay seeking care, which is partly attributed to problematic dermatology access.1, 3 On the other hand, misdiagnoses frequently occur, even after multiple consultations with various
-
-
-
Mycosis fungoides‐like eruptions associated with abatacept Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-08 Daichi Hoshina, Yuri Nagata
-
Janus kinase inhibitor Abrocitinib as an Off‐Label treatment for tattoo granuloma with uveitis (TAGU) Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-07 Yutong Yang, Jia Yan, Jin Yang, Peiru Wang, Yeqiang Liu, Xiuli Wang
-
Paediatric indications and dosing guidance for advanced targeted treatments in Australia Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-06 Patrick D Mahar, Susan J Robertson, David Orchard, Christopher Baker, Peter Foley
As with adults, paediatric patients may benefit from a number of advanced targeted therapies for inflammatory skin disease. This brief report aims to be an accessible reference tool with respect to regulatory approval and reimbursement of these treatments within Australia.
-
Treatment of lichen planopilaris with Janus kinase inhibitors Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Gabriela A. Gonzalez Matheus, Kiarash Khosrotehrani
CONFLICT OF INTEREST STATEMENT All authors declare that they have no conflicts of interest.
-
Quantitative analysis of the dermoscopy image to evaluate the efficacy of facial port‐wine stains (PWS) treatment Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-05 Yuanbo Huang, Jun Yang, Mingye Bi, Wen Ju, Lichao Zhang, Lingbo Bi, Yimei Du, Bin Chen, Weixin Fan
-
Features of tattoo‐associated cutaneous lymphoid hyperplasia on reflectance confocal microscopy and line‐field confocal optical coherence tomography Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-05 C. Ariasi, G. Licata, G. Perazzolli, F. Tonon, M. Venturini, P. G. Calzavara‐Pinton, S. Soglia
The popularity of tattoos has led to an increase in associated skin reactions, including complications such as infection, allergic reactions and rare conditions such as tattoo‐induced cutaneous lymphoid hyperplasia (CLH). CLH is a benign lymphoproliferative reaction with clinical features resembling malignant cutaneous lymphomas. Non‐invasive diagnostic tools like reflectance confocal microscopy (RCM)
-
Systematic scoping review on the barriers to access of biologics in moderate‐to‐severe adult atopic dermatitis Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-05 Vincent Wan, Alireza Habibi, Parsa Abdi, Ilya Mukovozov, Rachel N. Asiniwasis, Howard I. Maibach
To the editor, Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disorder associated with significant psychosocial comorbidity. Biologic treatment has provided patients with previously recalcitrant moderate-to-severe AD an opportunity to regain near-normal qualities of life. However, despite favourable efficacy and safety profiles, prescription rates remain low relative to the number of
-
Local injection of micro‐dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-05 Chaojing Zhou, Dandan Chen, Ziyue Diao, Yufei Wang, Yiyun Hou, ZhiQiang Yin
We present a palmoplantar pustulosis case partially resistant to systemic IL‐17A inhibitor (ixekizumab) treatment, and then receiving a local injection of 0.1 mL micro‐dose (1 mg) IL‐23 inhibitor (guselkumab) every 4 weeks for four times. The paradoxical lesion disappeared rapidly following local injection and there was no recurrence after 8 weeks of drug withdrawal. This is the first clinical report
-
Occupational contact dermatitis to Tanacetum cinerariifolium without sensitivity to sesquiterpene lactone mix or Compositae mix Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-03-02 Ashwin Kieran Rajagopalan, Bishakha Rajagopalan
A 44-year-old man presented with a two-and-a-half-year history of an itchy recurrent facial rash, occurring during the summer. He was employed at a company which made pyrethrins for insecticide manufacturers. His work included unloading and processing pyrethrum daisies (Tanacetum cinerariifolium) into pallets. He developed the rash after occupational exposure to the daisies, lasting 2–4 weeks each
-
Terra firma‐forme dermatosis displays bright blue plaques in Ultraviolet‐Induced Fluorescence Dermatoscopy Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Katarzyna Korecka, Anna Słomiak‐Wąsik, Aleksandra Dańczak‐Pazdrowska, Ryszard Żaba, Adriana Polańska
-
Lower limb lymphangioma circumscriptum: The guiding sign for the diagnosis of Maffucci syndrome Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Álvaro Martínez‐Doménech, Altea Esteve‐Martínez, Gemma Pérez‐Pastor, Jose Luis Sánchez‐Carazo, Amparo Pérez‐Ferriols
-
Dupilumab for atopic dermatitis in children with idiopathic nephrotic syndrome treated with cyclosporin: a report of two cases Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Marcelo B. Lucca, Julia K. Recuero, Daniel Lorenzini, Magda B. Weber
-
A rare case of unique purpuric circular eruption in association with Capnocytophaga canimorsus bacteremia Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Tatiana Ninkov, Justin Bui, Edward Raby, Benjamin Andrew Wood, Nima Mesbah Ardakani
-
Aquagenic pruritus successfully treated with upadacitinib Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Rodrigo Peñuelas Leal, Carolina Labrandero Hoyos, Andrés Grau Echevarría, Javier Lorca Sprohnle, Andrés Casanova Esquembre, Daniel Blaya Imbernon, Malena Finello, Violeta Zaragoza Ninet
-
Erythema induratum of Bazin during successful treatment of atopic dermatitis with dupilumab Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Chaojing Zhou, Ting Su, Yufei Wang, Yiyun Hou, ZhiQiang Yin, Jiping Xia
-
Adult genital psoriasis: An updated review for clinicians Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Michelle Wu, Gayle Fischer
Genital psoriasis is a chronic inflammatory skin condition that has been reported in up to 63% of patients with psoriasis on other parts of their skin. It has a profound impact on quality of life and sexual function which is often overlooked by current severity scores. Despite its prevalence and disease burden, genital psoriasis remains largely under‐reported and under‐treated. Historically, this was
-
Alterations in epidermal stem cells within the pilosebaceous unit in atrophic acne scars Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Dong Hyo Kim, Ji Young Yoon, Jun Hyo Lee, Dae Hun Suh
BackgroundAtrophic acne scarring is a common sequela of inflammatory acne, causing significant problems for affected patients. Although prolonged inflammation and subsequent aberrant tissue regeneration are considered the underlying pathogenesis, the role of epidermal stem cells, which are crucial to the regeneration of pilosebaceous units, remains unknown.ObjectivesTo examine the changes occurring
-
Cases with the H syndrome presenting with skin and bone findings Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Hulya Kose, Merve Deniz Baskaya, Sara Sebnem Kilic
BackgroundThe H syndrome is an autosomal recessive disease characterized by hyperpigmentation, hypertrichosis and sensorineural hearing loss.MethodsA mutation in the coding of the human equilibrative nucleoside transporter 3 (hENT3) within the SLC29A3 gene on chromosome 10q22 leads to the manifestation of this disease. In this report, we present two cases of H syndrome.ResultsThe first patient exhibits
-
Beyond the surface: Ultraviolet‐induced fluorescence dermatoscopy in the diagnosis of segmental porokeratosis Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Bengu Nisa Akay
-
Effectiveness and diagnostic accuracy of teledermatology for the assessment of skin conditions Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Nikesh Patel, Nada Aboukhatwah, Ben Esdaile
BackgroundTeledermatology provides a platform for swift specialist advice without the potential need for face‐to‐face review. Our objectives were to investigate the effectiveness, accuracy and diagnostic concordance of the platform with regard to the remote management of skin conditions.MethodsWe undertook a single‐centre, retrospective chart review over a 1‐year period, comprising a total of 1703
-
Minimum labelling requirements for dermatology artificial intelligence‐based Software as Medical Device (SaMD): A consensus statement Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Åsa Ingvar, Ayooluwatomiwa Oloruntoba, Maithili Sashindranath, Robert Miller, H. Peter Soyer, Pascale Guitera, Tony Caccetta, Stephen Shumack, Lisa Abbott, Chris Arnold, Craig Lawn, Alison Button‐Sloan, Monika Janda, Victoria Mar
Background/ObjectivesArtificial intelligence (AI) holds remarkable potential to improve care delivery in dermatology. End users (health professionals and general public) of AI‐based Software as Medical Devices (SaMD) require relevant labelling information to ensure that these devices can be used appropriately. Currently, there are no clear minimum labelling requirements for dermatology AI‐based SaMDs
-
Successful infliximab treatment in siblings with Netherton syndrome: Unveiling a novel SPINK5 gene variant and literature review Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Nazmiye Selin Salici, Adil Ozcanli, Gunel Rasulova, Ayse Nazli Basak, Seyma Tekgul, Secil Vural
Netherton syndrome (NS) is a rare autosomal recessive genodermatosis. In this article, we present two siblings with NS who harbour a novel variant in the SPINK5 gene and were treated with infliximab infusions. Both patients exhibited the characteristic clinical triad of NS, and their whole exome sequencing analysis revealed a homozygous variant, c.1820+53G>A, in the SPINK5 gene. Notably, this is the
-
Investigating causal relationships between the gut microbiota and inflammatory skin diseases: A Mendelian randomization study Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Yunfan Gu, Weiming Zhang, Wenting Zhao, Xianyu Zeng
BackgroundNumerous inflammatory skin diseases are associated with the gut microbiota. Studies of the association between gut microbiota and inflammatory skin diseases have yielded conflicting results owing to confounding factors, and the causal relationship between them remains undetermined.MethodsTwo‐sample Mendelian randomization (MR) was used to examine the association between gut microbiota and
-
Alterations in gut microbiome associated with severity of atopic dermatitis in infants Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-29 Xiaoyi Liu, Meiqin Cai, Meiru Chen, Ji Chen, Tingyu Zhu, Shiyin Wu, Jie Jia
BackgroundAtopic dermatitis (AD) often arises in infancy, and gut microbial dysbiosis is associated with the development of AD. However, less is known about specific changes in early‐life gut microbiome associated with AD and AD severity. This study aims to reveal the gut microbial composition and function profiles associated with the severity of AD in infants.MethodsSixty‐two infants (mean [SD] age
-
Self-reported clinical features and treatment effectiveness of Papillon–Lefèvre syndrome patients from five Latin American countries: A cross-sectional online survey study Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-13 Daniela Alfaro-Sepúlveda, Pía Parra Salinas, Fernando Valenzuela, Carmen Gloria Gonzalez, Valentina Burckhardt-Bravo, Dominga Ferrari-Sande
Most studies about Papillon–Lefèvre syndrome (PLS) are limited to case reports and patients of the same nationality. This study aimed to determine the self-reported prevalence of signs, symptoms and treatment effectiveness in PLS patients from five Latin American countries.
-
Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al. Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-09 James P. Pham, Akshay Flora, John W. Frew
Pyoderma gangrenosum (PG) is a chronic, ulcerative skin condition characterised by dysregulated responses of neutrophils, T cells, macrophages and fibroblasts to antigenic stimuli.1 Our understanding of the aetiology of PG to guide targeted therapeutics has been hindered by a lack of validated animal models, with a murine skin model only recently established by Jatana et al.2 While this model is a
-
Nivolumab-induced lichenoid penile ulceration and re-emergent mucocutaneous eruption treated with hydroxychloroquine Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-02-09 Virginia A. Headd, August Mathien, Susan Pei, Drew Kuraitis
CONFLICT OF INTEREST STATEMENT The authors declare no relevant conflicts of interest.
-
Real-life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-01-24 Caldarola Giacomo, Trovato Emanuele, Burlando Martina, Capalbo Eugenio, Diotallevi Federico, Lora Viviana, Pinto Lorenzo Maria, Gaeta Shumak Ruslana, Fastame Maria Thais, Mariani Marco, Campione Elena, Offidani Annamaria, Parodi Aurora, Prignano Francesca
Palmoplantar (PP) psoriasis is considered one of the most hard-to-treat areas with important impact on patients' quality of life, and few data are available about the efficacy of dimethylfumarate (DMF) on these areas. In our noninterventional multicentre retrospective cohort study of patients with PP psoriasis treated with DMF, effectiveness was evaluated as mean pp Psoriasis Area and Severity Index
-
Zinc deficiency or genetic mutations?—A case report of hair heterochromia in the context of MC1R genetic mutations Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-01-12 Zhang Lei, Wan Yingcai, Wu Jianbo
Hair heterochromia may be caused by different mechanisms. At clinical work, we found a Chinese boy whose hair colour gradually turned to red. We record the diagnosis and treatment process and follow-up situation, finally find that altered hair colour phenotype is due to MC1R genetic mutations, rather than zinc deficiency. This rarely red hair colour phenotype improve our understanding of hair heterochromia
-
Successful treatment of xanthoma disseminatum with pulsed dye laser: A case report Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-01-08 Jin Woong Jung, Joon-Goon Kim, Albaraa Abdullatif A. Alwabel, Yeon Woo Jung, Kee-Yang Chung
Xanthoma disseminatum is a rare form of non-Langerhans cell histiocytosis with limited treatment options due to its unknown aetiology and diffuse skin lesions. This case report presents the successful treatment of a 31-year-old male with severe pan-facial xanthoma disseminatum lesions following a facial burn and traumatic brain injury resulting from a car accident. After 5 sessions of monthly pulsed
-
The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab Australas. J. Dermatol. (IF 2.0) Pub Date : 2024-01-08 Anthony Honigman, Hnin P. Oo, Richard Macdonell, Johannes S. Kern
Prescription of biological disease-modifying agents for inflammatory cutaneous disease has become increasingly popular given their favourable safety profile and high rates of efficacy. Patients with multiple medical comorbidities may require the use of simultaneous biological therapies to manage coexistent conditions. There is a paucity of literature regarding patient safety and outcomes of those receiving
-
Single-stage reconstruction of a large defect of the ear Australas. J. Dermatol. (IF 2.0) Pub Date : 2023-12-29 Quentin Samaran, Pierre Stoebner, Bernadette Ovtchinnikoff
To reconstruct a large anterior skin and cartilage defect of the upper half of the external ear in an elderly patient after cancer surgery, different techniques are possible, but single-stage procedures should be advised. Combining flaps with reliable vascular supply, like the revolving door post-auricular flap and a mastoid advancement flap, is an attractive single-stage reconstructive option to rebuild
-
The role of micrometastasis in high-risk skin cancers Australas. J. Dermatol. (IF 2.0) Pub Date : 2023-12-29 Robert Sinclair, Xin Lin Wong, Stephen Shumack, Christopher Baker, Beth MacMahon
The propensity to metastasize is the most important prognostic indicator for solid cancers. New insights into the mechanisms of early carcinogenesis have revealed micrometastases are generated far earlier than previously thought. Evidence supports a synergistic relationship between vascular and lymphatic seeding which can occur before there is clinical evidence of a primary tumour. Early vascular seeding
-
Jacquet erosive dermatitis associated with commercial barrier cream Australas. J. Dermatol. (IF 2.0) Pub Date : 2023-12-22 Minja Coelho, Jean-Marie Tan, Natalie Ling
Jacquet erosive dermatitis (JED) is a rare, severe form of napkin dermatitis associated with friction and irritant exposure in the napkin area. The condition typically causes erosions and erythematous punched-out ulcerations. We present two cases of JED in infants associated with the use of a common brand barrier cream Curash. This appeared to present following a change of several active ingredients
-
Biologics for inherited disorders of keratinisation: A systematic review Australas. J. Dermatol. (IF 2.0) Pub Date : 2023-12-21 Michelle K. Y. Chen, Alice L. Flanagan, Deshan F. Sebaratnam, Yaron Gu
Recent literature highlights the potential of biologics in the management of inherited disorders of keratinisation. In this study, we conducted a systematic review of existing literature on treatment outcomes of inherited keratinisation disorders treated with biologics.